Exelixis, Inc. (Nasdaq:EXEL) announced today that George A. Scangos,
PhD, President and Chief Executive Officer of Exelixis, will present at
the JMP Securities 3rd Annual Healthcare Focus Conference at 11:30 a.m.
ET/8:30 a.m. PT on Monday, October 6, 2008. Dr. Scangos will discuss
updates to the company’s development pipeline
and corporate strategy.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product
pipeline includes investigational compounds in phase 3, phase 2, and
phase 1 clinical development. Exelixis has established strategic
corporate alliances with major pharmaceutical and biotechnology
companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech,
Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please
visit the company’s web site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Exelixis, Inc.
Charles Butler, 650-837-7277 (Investors)
Senior
Director
Corporate Communications & Investor Relations
cbutler@exelixis.com
Soleil
Maxwell Harrison, 650-837-7012 (Media)
Senior Manager
Corporate
Communications
sharrison@exelixis.com
